Werewolf Therapeutics’ (HOWL) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report released on Wednesday morning, MarketBeat.com reports. The brokerage currently has a $8.00 price target on the stock.

Several other equities analysts have also recently issued reports on HOWL. JMP Securities reduced their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Werewolf Therapeutics in a report on Wednesday.

Werewolf Therapeutics Stock Down 0.8 %

HOWL opened at $1.20 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. Werewolf Therapeutics has a 1 year low of $1.03 and a 1 year high of $6.89. The firm has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.81. The company has a market cap of $53.48 million, a PE ratio of -0.78 and a beta of 0.37.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. Sell-side analysts expect that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HOWL. Walleye Capital LLC increased its position in Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares during the period. PFM Health Sciences LP boosted its stake in Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after purchasing an additional 157,673 shares in the last quarter. State Street Corp boosted its stake in Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after purchasing an additional 52,528 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Werewolf Therapeutics during the third quarter worth $45,000. Finally, Barclays PLC raised its position in shares of Werewolf Therapeutics by 130.1% during the third quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after acquiring an additional 30,990 shares during the last quarter. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.